Personlized therapy for MDS: Advancements and the future
Torsten Haferlach, MD, PhD, of the Munich Leukaemia laboratory, Munich, Germany, highlights the rapidly expanding field of molecular diagnostics, moving us towards personalized medicine for patients w...
Author: VJHemOnc
Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts
Resistance/intolerance to second generation TKIs in CML: what to do next?
If resistance occurs to second generation TKIs in chronic myeloid leukemia (CML) patients, what is the next best option? Here, Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, explores t...
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Overcoming venetoclax resistance in AML with MCL1 inhibition
Venetoclax monotherapy has yielded disappointing results in acute myeloid leukemia (AML) because resistance develops along with the propagation of MCL1-expressing clones. Here, Marina Konopleva, MD, P...
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Midostaurin and quizartinib: improving survival and day-to-day life in AML
Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the effectiveness of drugs currently on the market to treat acute myeloid leukemia (AML) at the 2018 Society of Hemat...
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
iFCG yields unprecedented MRD negativity in CLL
FCR chemoimmunotherapy is most effective in the IGVH mutated, non-17p deletion chronic lymphocytic leukemia (CLL) patient subgroup. With the advent of novel drugs in the field however, Nitin Jain, MD,...
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
CAR T-cells in CLL: the current landscape
While CAR T-cells are an approved therapy option in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), the research in chronic lymphocytic leukemia (CLL) is somewhat behind....
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Update on ENESTop: TFR in CML after discontinuing nilotinib
The ENESTop trial (NCT01698905) investigated treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) after discontinuing nilotinib, following the acheivement of a deep molecular...
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel approaches to first line CLL treatment
First line therapies for chronic lymphocytic leukemia (CLL) have developed beyond the historic approach of giving all patients FCR chemoimmunotherapy. In this video, recorded at the 2018 Society of He...
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Venetoclax combinations effective in elderly AML
While venetoclax is widely used in chronic lymphocytic leukemia (CLL) to good effect, previous studies have suggested that the drug does not yield such good results in acute myeloid leukemia (AML). In...
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Benefits of second generation TKIs for CML in the frontline
Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the benefits of second generation TKIs for the frontline treatment of chronic myeloid leukemia (CML). These more potent inhibit...
Author: VJHemOnc
Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Uses of NGS in AML
Christopher Gibson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses the multiple uses of next-generation sequencing (NGS) in the management of acute myeloid leukemia (AML). Using NGS, clona...
Author: VJHemOnc
Added: 09/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 19, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD testing in acute leukemias
Here, Josep-Maria Ribera, MD, PhD, of Germans Trias i Pujol University Hospital, Barcelona, Spain, discusses the potential of measurable residual disease (MRD) testing to determine treatment outcome i...
Author: VJHemOnc
Added: 08/31/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 31, 2018 Category: Cancer & Oncology Source Type: podcasts
Personalized therapy in leukemia: a case study
An improved understanding of the disease biology of leukemia has driven personalized therapy that has helped lower the risk of relapse in patients. Here, Patrick Kiel, PharmD, BCOP, BCPS, of Indiana U...
Author: VJHemOnc
Added: 08/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 29, 2018 Category: Cancer & Oncology Source Type: podcasts
Changes in the AML treatment landscape
Richard Stone, MD, of the Dana-Farber Cancer Institute, Boston, MA, talks about the latest advances that have been made in acute myeloid leukemia (AML), including recent drug approvals after numerous ...
Author: VJHemOnc
Added: 08/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 29, 2018 Category: Cancer & Oncology Source Type: podcasts
EBMT 2018 overview: AML pathophysiology
Antonio Almeida, MD, PhD, of the Instituto Portugus de Oncologia Francisco Gentil, Lisbon, Portugal, gives an overview of acute myeloid leukemia (AML) pathophysiology at the European Society for Bloo...
Author: VJHemOnc
Added: 08/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 29, 2018 Category: Cancer & Oncology Source Type: podcasts
